Virus-leukocyte interactions are critical to the outcome of infections with potentially oncogenic viruses. Leukocytes limit the replication of both viruses and cells transformed by viruses. However, viruses may also replicate in leukocytes and alter their function, inhibiting an effective response. This proposal will study the interactions of potentially oncogenic human herpesviruses with human leukocytes. Cytomegalovirus is a major cause of human disease, as a teratogen, opportunistic pathogen following blood transfusions or immunosuppression, and as a possible oncogen. We have demonstrated that CMV has a potent immunosuppressive effect onleukocyte function. The mechanisms of this CMV-induced hyporesponsiveness will be explored. Functional evaluation of specific leukocyte subsets and their interactions will be undertaken in vivo and in vitro. Attempts will be made to correct or reconstruct CMV-induced defective leukocyte responses. CMV-leukocyte associations will also be exploited to help develop rapid diagnostic assays for CMV artigens in infected granulocytes. Herpes simplex virus may also have complex interactions with human leukocytes. We have established a model of herpes simplex virus persistent infection of human T lymphoblasts. This persistent infection can either be productive or non-productive, depending on manipulations in vitro. Addition of antiviral agents (antibody, interferon, acyclovir) or temperature elevation can result in non-productive infection. Removal of antivirals, lowering of temperature, addition of phytohemagglutinin or 5-azacytidine can induce productive infection. The mechanisms underlying these events will be explored in vitro, and attempts will be made to determine the importance of methylation in the maintenance of non-productive infections. In situ molecular hybridization techniques will be used to determine the numbers of cells that are infected during productive and non-productive infections. The same techniques will be used to investigate the recent suggestion that certain human diseases, e.g. Behcet's syndrome, are associated with lymphocytes carrying latent herpes simplex DNA. Our herpes model will also be used to explore interactions between antiviral agents and persistent infections.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA012464-20
Application #
3163651
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1979-06-01
Project End
1992-05-31
Budget Start
1990-06-01
Budget End
1991-05-31
Support Year
20
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Tremblay, Cecile L; Giguel, Francoise; Kollmann, Christopher et al. (2002) Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 46:1336-9
Rusconi, S; La Seta Catamancio, S; Citterio, P et al. (2000) Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. J Virol 74:9328-32
Tremblay, C L; Kollmann, C; Giguel, F et al. (2000) Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 25:99-102
Rusconi, S; Merrill, D P; La Seta Catamancio, S et al. (2000) In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs. Antivir Ther 5:199-204
Tremblay, C L; Giguel, F; Merrill, D P et al. (2000) Marked differences in quantity of infectious human immunodeficiency virus type 1 detected in persons with controlled plasma viremia by a simple enhanced culture method. J Clin Microbiol 38:4246-8
Merrill, D P; Martinez-Picado, J; Tremblay, C et al. (1999) Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. J Infect Dis 179:345-51
Tremblay, C; Merrill, D P; Chou, T C et al. (1999) Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. J Acquir Immune Defic Syndr 22:430-6
Oh, M D; Merrill, D P; Hirsch, M S (1999) Induction and maintenance treatment regimens for HIV-1 infection in vitro. Antivir Ther 4:29-34
Martinez-Picado, J; Savara, A V; Sutton, L et al. (1999) Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73:3744-52
Merrill, D P; Manion, D J; Chou, T C et al. (1997) Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Infect Dis 176:265-8

Showing the most recent 10 out of 56 publications